Lysophospholipids in Lung Inflammatory Diseases

Adv Exp Med Biol. 2021:1303:373-391. doi: 10.1007/978-3-030-63046-1_20.

Abstract

The lysophospholipids (LPLs) belong to a group of bioactive lipids that play pivotal roles in several physiological and pathological processes. LPLs are derivatives of phospholipids and consist of a single hydrophobic fatty acid chain, a hydrophilic head, and a phosphate group with or without a large molecule attached. Among the LPLs, lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) are the simplest, and have been shown to be involved in lung inflammatory symptoms and diseases such as acute lung injury, asthma, and chronic obstructive pulmonary diseases. G protein-coupled receptors (GPCRs) mediate LPA and S1P signaling. In this chapter, we will discuss on the role of LPA, S1P, their metabolizing enzymes, inhibitors or agonists of their receptors, and their GPCR-mediated signaling in lung inflammatory symptoms and diseases, focusing specially on acute respiratory distress syndrome, asthma, and chronic obstructive pulmonary disease.

Keywords: G protein–coupled receptors; Lung inflammation; Lysophosphatidic acid; Lysophospholipids; Signaling pathway; Sphingosine-1-phosphate.

MeSH terms

  • Lung
  • Lysophospholipids*
  • Receptors, G-Protein-Coupled
  • Signal Transduction
  • Sphingosine*

Substances

  • Lysophospholipids
  • Receptors, G-Protein-Coupled
  • Sphingosine
  • lysophosphatidic acid